552 completed, 73 unknown, 68 terminated, 31 active not recruiting. 793 Phase 3, 86 Phase 2.
Follow Bone Diseases: new trials by email Literature Review of Bone Diseases trials Research Report on Bone Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testosterone Therapy With or Without Finasteride After Spinal Cord Injury: TRT-SCI Trial testosterone cypionate, finasteride, placebo injection - Spinal Cord Injury, Spinal Cord Injuries | Phase 2 / Phase 3 | Not yet recruiting | VA Office of Research and Development | 300 | 2027-10-01 | 2026-08-04 |
| Phase 3 Long Term Safety Extension Study of LUM-201 in Children With Growth Hormone Deficiency LUM-201 - Growth Hormone Deficiency (GHD) | Phase 3 | Not yet recruiting | Lumos Pharma | 150 | 2027-02-01 | 2026-07-08 |
| A Study of Zasocitinib in Adults With Psoriatic Arthritis (LATITUDE PsA NeXt) Placebo, Zasocitinib - Psoriatic Arthritis | Phase 3 | Not yet recruiting | Takeda | 644 | 2027-01-11 | 2026-10-27 |
| Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study Completers Deucravacitinib - Systemic Lupus Erythematosus, Sjögren's Disease | Phase 3 | Not yet recruiting | Bristol-Myers Squibb | 2300 | 2026-12-31 | 2026-09-03 |
| Clinical Trial Evaluating the Efficacy and Safety of Navepegritide and Lonapegsomatropin in Achondroplasia Dual therapy with navepegritide and lonapegsomatropin, Dual therapy with navepegritide and placebo for lonapegsomatropin, Dual therapy with lonapegsomatropin and placebo for navepegritide - Achondroplasia | Phase 3 | Not yet recruiting | Ascendis Pharma A/S | 144 | 2026-11-01 | 2026-11-12 |
| Spinal Bracing in Adults With Painful Degenerative Scoliosis: a Randomized Controlled Open Trial Custom-molded lumbar-sacral orthosis, Usual Care - Degenerative Scoliosis, Scoliosis Idiopathic | Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 130 | 2026-09-01 | 2026-05-01 |
| PRESTO: A Phase III Randomised Controlled Trial of Dose-escalated Proton Beam Therapy Versus Standard of Care Radiotherapy for Functioning Pituitary Tumours Standard dose Intensity-Modulated Radiation Therapy (IMRT), Standard dose Proton Beam Therapy (PBT), Escalated dose Proton Beam Therapy (PBT) - Acromegaly Due to Pituitary Adenoma, Cushing's Disease | Phase 3 | Not yet recruiting | University College, London | 82 | 2026-09-01 | 2026-10-01 |
| Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer Futibatinib, Zimberelimab, Durvalumab - Biliary Tract Cancer | Phase 3 | Recruiting | Taiho Pharmaceutical Co., Ltd. | 784 | 2026-06-24 | 2026-07-17 |
| Efficacy and Safety of Novosis Putty in Transforaminal Lumbar Interbody Fusion for Patients With Lumbar Degenerative Disc Disease Novosis Putty, Standard of Care - Degenerative Disc Disease | Phase 3 | Recruiting | CGBio Inc. | 316 | 2026-06-11 | 2026-08-26 |
| GB06 Phase III Trial for Pediatric Growth Hormone Deficiency GB06, Norditropin®FlexProTM - Growth Hormone Deficiency (GHD), Growth Hormone Deficiency in Children | Phase 3 | Recruiting | Kexing Biopharm Co., Ltd. | 192 | 2026-06-06 | 2026-06-10 |
| A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle autologous cultured chondrocytes on porcine collagen membrane, Bone Marrow Stimulation - Chondral Defect, Articular Cartilage Defect | Phase 3 | Recruiting | Vericel Corporation | 309 | 2026-05-28 | 2026-11-05 |
| Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency LUM-201, Matched Placebo (Capsules) - Growth Hormone Deficiency (GHD) | Phase 3 | Recruiting | Lumos Pharma | 150 | 2026-05-20 | 2026-10-19 |
| Prospective, Randomized, Multicenter Clinical Trial of Bisphosphonates Combined With Vancomycin for the Treatment of Cierny-Mader Type I and III Osteomyelitis Bisphosphonates Combined with Vancomycin, Vancomycin - Osteomyelitis (Refractory) | Phase 3 | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 280 | 2026-05-01 | 2026-02-27 |
| MDT-0123 Japan Study MDT-0123, ICBG - Disc Degeneration, Spinal Deformity | Phase 3 | Recruiting | Medtronic Spinal and Biologics | 140 | 2026-04-24 | 2026-09-09 |
| Continuous Antibiotic Infusion In Children Benzylpenicillin - Infection | Phase 3 | Recruiting | Tampere University Hospital | 150 | 2026-04-21 | 2026-05-08 |
| Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia BMN 333, Vosoritide Injection [Voxzogo] - Achondroplasia | Phase 2 / Phase 3 | Recruiting | BioMarin Pharmaceutical | 160 | 2026-04-20 | 2026-10-22 |
| Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis Imperfecta Vitamin D, Calcium - Osteogenesis Imperfecta | Phase 3 | Recruiting | Amgen | 71 | 2026-03-18 | 2026-06-22 |
| Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis Zasocitinib - Psoriatic Arthritis | Phase 3 | Recruiting | Takeda | 1182 | 2026-03-11 | 2026-11-12 |
| A Study to Evaluate the Efficacy and Safty of 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA) 608, Placebo - Axial Spondyloarthritis, Non-Radiographic | Phase 3 | Not yet recruiting | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 380 | 2026-03-09 | 2026-01-16 |
| Efficacy and Safety of Xeligekimab in the Treatment of Non-Radiographic Axial Spondyloarthritis Xeligekimab injection - Nr-axial Spondyloarthritis, Non-Radiographical Axial Spondyloarthritis | Phase 2 / Phase 3 | Not yet recruiting | Lingli Dong | 40 | 2026-01-31 | 2026-01-14 |
Showing 20 of 793. Sign in to see all of them.
Osteoporosis (194) · Arthritis, Psoriatic (105) · Spondylitis, Ankylosing (82) · Bone Diseases, Metabolic (75) · Osteoporosis, Postmenopausal (74) · Dwarfism, Pituitary (57) · Acromegaly (33) · Axial Spondyloarthritis (26) · Intervertebral Disc Degeneration (23) · Psoriasis (23) · Intervertebral Disc Displacement (22) · Bone Neoplasms (21) · Dwarfism (20) · Musculoskeletal Diseases (19)
Musculoskeletal Diseases (774) · Nutritional and Metabolic Diseases (301) · Metabolic Diseases (299) · Spinal Diseases (268) · Bone Diseases, Metabolic (216) · Joint Diseases (211) · Spondylitis (202) · Arthritis (196) · Spondylarthropathies (193) · Spondylarthritis (191) · Skin and Connective Tissue Diseases (164) · Nervous System Diseases (124) · Pathological Conditions, Signs and Symptoms (124) · Bone Diseases, Developmental (122)
Denosumab (44) · Zoledronic Acid (41) · Alendronate (40) · Human Growth Hormone (36) · Risedronic Acid (32) · secukinumab (29) · Adalimumab (26) · Teriparatide (24) · Cholecalciferol (23) · Calcium (21) · Vitamin D (21) · Etanercept (15) · Growth Hormone (14) · Ibandronic Acid (14) · golimumab (14)
Novartis Pharmaceuticals (52) · Amgen (38) · Eli Lilly and Company (33) · Pfizer (20) · Janssen Research & Development, LLC (14) · Organon and Co (14) · Merck Sharp & Dohme LLC (13) · Hoffmann-La Roche (12) · UCB Biopharma SRL (12) · Ipsen (11) · Abbott (8) · Assistance Publique - Hôpitaux de Paris (8) · Novo Nordisk A/S (8) · Wyeth is now a wholly owned subsidiary of Pfizer (8) · AbbVie (7)
United States (351) · Germany (172) · Canada (162) · Poland (155) · Spain (149) · United Kingdom (149) · France (139) · Italy (130) · Czechia (118) · Australia (116) · Hungary (112) · Russia (104) · Belgium (99) · China (82) · Japan (76)
PMID 38979716, PMID 31203228, PMID 38446397, PMID 37316690, PMID 40194794, PMID 41807031, PMID 41965705, PMID 42386286, PMID 21037195, PMID 34618347, PMID 35305260, PMID 38488975, PMID 39120849, PMID 33722947, PMID 34795065, PMID 36792107, PMID 39120848, PMID 40241921, PMID 30018799, PMID 30473179, PMID 31077258, PMID 31112005, PMID 31776637, PMID 31909868, PMID 31964419, PMID 32006348, PMID 32352653, PMID 32816215, PMID 33227175, PMID 33351179, PMID 34536218, PMID 34773130, PMID 34870800, PMID 35393269, PMID 35429281, PMID 36282526, PMID 36380045, PMID 36526796, PMID 36642439, PMID 36931693, PMID 36958766, PMID 36995469, PMID 37906417, PMID 37982966, PMID 38488976, PMID 38683479, PMID 38754125, PMID 39151033, PMID 39215949, PMID 39534481
2023 (16), 2015 (15), 2016 (14), 2009 (12), 2018 (12), 2014 (11), 2017 (10), 2019 (10), 2004 (4), 2008 (4), 2005 (2), 2025 (2), 1UL1RR025758 (1), N01AR002245 (1), P50AR044855 (1)